C4X Discovery is using its unique proprietary technologies to build a pipeline of high quality small molecule drug candidates addressing valuable markets with high unmet medical need.
At present, C4X Discovery’s portfolio targets addiction, diabetes, inflammatory diseases (COPD and psoriasis) and oncology and includes small molecule versions of marketed biologics.
The Company's first drug candidate is an oral Orexin-1 antagonist for the treatment of addiction, with its primary indication as an aid to smoking cessation. It is currently in pre-clinical development with a regulatory submission to conduct a Phase I clinical trial planned for late 2016. C4X Discovery is currently expanding its pipeline and expects to ultimately initiate more than 4 therapeutic projects each year at steady state. C4XD now has five therapeutic projects underway.
(Inititated Nov 15)
Hot GPCR targets lacking target protein crystal structure at project initiation
Marketed Biologics (clinically validated) with small molecule opportunity
Intracellular target protein structure available, novel hit finding less successful with conventional screening but enabled by C4X